Revance Therapeutics reported $127.18M in Cash and Equivalent for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cash And Equivalent Change
Adamas Pharmaceuticals ADMS:US 78.62M 10.17M
Aerie Pharmaceuticals AERI:US $ 61.85M 18.11M
ALKERMES ALKS:US $ 310.44M 52.1M
Biodelivery Sciences International BDSI:US 100.71M 19.14M
Bristol Myers Squibb BMY:US $ 13540M 2516M
Cara Therapeutics CARA:US $ 22.99M 656K
Coherus Biosciences CHRS:US $ 360.54M 30.8M
Eli Lilly And LLY:US $ 3788.2M 568.2M
Endo International Ordinary Shares ENDP:US $ 1568.66M 23.49M
Flexion Therapeutics FLXN:US $ 136.82M 29.2M
Gw Pharmaceuticals GWPH:US $ 458.1M 28.65M
Horizon Pharma HZNP:US $ 1068.55M 256.23M
Jazz Pharmaceuticals JAZZ:US 1000 0
Neurocrine Biosciences NBIX:US $ 311.1M 56.9M
Pacira Pharmaceuticals PCRX:US $ 134.04M 28.26M
Procter & Gamble PG:US $ 10370M 82M
Revance Therapeutics RVNC:US $ 127.18M 40.46M
Supernus Pharmaceuticals SUPN:US $ 215.28M 8.49M
Teva Pharmaceutical Industries TEVA:US $ 2045M 391M
Zogenix ZGNX:US $ 106.14M 28.81M